PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
infoPROCEPT BioRobotics is a small cap stock with a total market cap of 1.53B.
infoThey trade on the NASDAQ and had their IPO 1 year and 11 months ago.
infoPROCEPT BioRobotics currently employs 428 people.
infoAs of Wednesday, Aug 23 2023, PROCEPT BioRobotics’s share price is $30.4.
News Relating to PROCEPT BioRobotics
GlobeNewsWire
PROCEPT BioRobotics to Present at the 2023 Wells Fargo Healthcare Conference in Boston
Thursday Aug 17 2023 at 16:05
REDWOOD CITY, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) — PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2023 Wells Fargo Healthcare Conference in Boston. Management is scheduled to present on Thursday, September 7 at 3:00 p.m. Eastern Time. A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.
Seeking Alpha
Procept BioRobotics: Adding Value Through Robust Unit Economics, Reiterate Buy
Thursday Aug 10 2023 at 15:24
PRCT’s aquablation therapy has shown strong growth, with revenues of $57.5mm in Q2 FY’23. The company’s economic levers include new system placements, and growth from its installed base, with a record number of systems placed in Q2. Net-net, reiterate buy, eyeing a $40 price objective.
Zacks Investment Research
PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Tops Revenue Estimates
Thursday Jul 27 2023 at 10:12
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.43 per share a year ago.
GlobeNewsWire
PROCEPT BioRobotics to Report Second Quarter 2023 Financial Results on July 27, 2023
Tuesday Jul 11 2023 at 16:03
REDWOOD CITY, Calif., July 11, 2023 (GLOBE NEWSWIRE) — PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2023 before market open on Thursday, July 27, 2023. The Company’s management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time.
Seeking Alpha
Procept BioRobotics: Adding For 2023 Rebound
Tuesday May 30 2023 at 10:19
Procept had weak results on adding fewer than expected Aquabeam devices in Q1 of 2023, leading to a fall in the shares. Procept has strong potential in urology where its Aquablation technology has many potential indications. The company should rebound throughout the year on increased consumable usage and new deployments of its device through IDNs.
InvestorPlace
7 Growth Stocks That Could Double Your Money in 2023
Sunday May 14 2023 at 14:57
While the recent slow activity in the major indices clouds the narrative, you can still enjoy opportunities for growth stocks that could double your money. To be sure, you must be willing to accept some risks.
Seeking Alpha
PROCEPT BioRobotics Corporation (PRCT) Q1 2023 Earnings Call Transcript
Sunday Apr 30 2023 at 09:31
Start Time: 08:00 January 1, 0000 8:56 AM ET PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q1 2023 Earnings Conference Call April 27, 2023, 08:00 AM ET Company Participants Reza Zadno – President and CEO Kevin Waters – EVP and CFO Matt Bacso – VP, IR and Business Operations Conference Call Participants Craig Bijou – Bank of America Joshua Jennings – Cowen Ryan Zimmerman – BTIG Chris Pasquale – Nephron Research Neil Chatterji – B. Riley Richard Newitter – Truist Nathan Treybeck – Wells Fargo Matthew Mishan – KeyBanc Operator Good morning, and welcome to the PROCEPT BioRobotics First Quarter 2023 Earnings Conference Call.
Zacks Investment Research
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
Thursday Apr 27 2023 at 09:52
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.39 per share a year ago.
Zacks Investment Research
Analysts Estimate PROCEPT BioRobotics Corporation (PRCT) to Report a Decline in Earnings: What to Look Out for
Thursday Apr 20 2023 at 11:26
PROCEPT BioRobotics Corporation (PRCT) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewsWire
PROCEPT BioRobotics to Report First Quarter 2023 Financial Results on April 27, 2023 and Present at the Bank of America 2023 Health Care Conference in Las Vegas
Wednesday Apr 05 2023 at 16:03
REDWOOD CITY, Calif., April 05, 2023 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2023 before market open on Thursday, April 27, 2023. The Company’s management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time.
GlobeNewsWire
PROCEPT BioRobotics Corp. to Present at the Virtual Key Bank Life Sciences & MedTech Investor Forum
Thursday Mar 02 2023 at 16:05
REDWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming Virtual Key Bank Life Sciences & MedTech Investor Forum. Management is scheduled to present on Tuesday, March 21 at 12:45 p.m. Eastern Time. A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.
Zacks Investment Research
PROCEPT BioRobotics Corporation (PRCT) Reports Q4 Loss, Tops Revenue Estimates
Tuesday Feb 28 2023 at 18:49
PROCEPT BioRobotics Corporation (PRCT) delivered earnings and revenue surprises of -5.66% and 0.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewsWire
PROCEPT BioRobotics Corp. to Present at the 43rd Annual Cowen Health Care Conference in Boston
Monday Feb 13 2023 at 16:02
REDWOOD CITY, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 43rd Annual Cowen Health Care Conference in Boston. Management is scheduled to present on Tuesday, March 7 at 12:50 p.m. Eastern Time. A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.
Seeking Alpha
Procept BioRobotics: Positioning Into FY22 Earnings (Technical Analysis)
Tuesday Feb 07 2023 at 09:56
PROCEPT BioRobotics endured a volatile start to the new year, eventually breaking above its longer-term resistance line. Market generated data is still supportive for a re-rating heading into its FY22 earnings.
GlobeNewsWire
PROCEPT BioRobotics Corp. to Present at the 41st Annual J.P. Morgan Healthcare Conference
Wednesday Dec 14 2022 at 16:05
REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference. Management is scheduled to present on Tuesday, January 10 at 9:45 a.m. Pacific Time. A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.
Seeking Alpha
Procept BioRobotics: Aquablation System Meaningful Insulator
Friday Nov 18 2022 at 16:20
PROCEPT BioRobotics Corporation reported 135% YoY Q3 revenue growth to $20.3mm. Growth was underscored by robotic system sales and utilization from current placements.
Seeking Alpha
PROCEPT BioRobotics Corporation (PRCT) Q3 2022 Earnings Call Transcript
Sunday Nov 06 2022 at 08:22
PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q3 2022 Earnings Call Conference Call November 3, 2022 4:30 PM ET Company Participants Matt Bacso – Vice President-Investor Relations Reza Zadno – Chief Executive Officer Kevin Waters – Senior Vice President and Chief Financial Office Conference Call Participants Craig Bijou – BofA Securities Nathan Treybeck – Wells Fargo Richard Newitter – Truist Securities Ryan Zimmerman – BTIG Neil Chatterji – B. Riley Matthew Mishan – KeyBanc Philip Coover – Goldman Sachs Joshua Jennings – Cowen Operator Good day.
Zacks Investment Research
PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Tops Revenue Estimates
Thursday Nov 03 2022 at 19:36
PROCEPT BioRobotics Corporation (PRCT) delivered earnings and revenue surprises of -8.51% and 17.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Investors Business Daily
Leading Medical Stocks, Including Sensus And Shockwave, Have Grown At Least 36% This Year
Wednesday Oct 05 2022 at 13:18
Biotech isn’t the only place investors in health care stocks can make money in 2022. Take a look at leading medical-equipment stocks.
Seeking Alpha
Procept BioRobotics Has Resources To Ramp Up Commercialization
Thursday Sep 01 2022 at 15:39
Procept BioRobotics went public in September 2021, raising approximately $164 million in an IPO. The firm is commercializing a water-based ablation device to treat benign prostatic hyperplasia, a common condition in older men.
GlobeNewsWire
PROCEPT BioRobotics Corp. to Present at 2022 Wells Fargo Healthcare Conference
Monday Aug 22 2022 at 16:03
REDWOOD CITY, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present and host a fireside chat at the upcoming 2022 Wells Fargo healthcare conference. Management is scheduled to present on Wednesday, September 7 at 9:10 a.m. Eastern Time. A live webcast of each event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.
Seeking Alpha
PROCEPT BioRobotics Corporation’s (PRCT) CEO Reza Zadno on Q2 2022 Results – Earnings Call Transcript
Sunday Aug 07 2022 at 00:19
PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Matt Bacso – Investor Relations Reza Zadno – Chief Executive Officer Kevin Waters – Chief Financial Officer Conference Call Participants Joshua Jennings – Cowen Craig Bijou – Bank of America Amit Hazan – Goldman Sachs Matthew Mishan – KeyBanc Neil Chatterji – B. Riley Operator Good afternoon, and welcome to PROCEPT BioRobotics Second Quarter Earnings Conference Call.
GlobeNewsWire
PROCEPT BioRobotics to Report Second Quarter 2022 Financial Results on August 4, 2022
Thursday Jul 14 2022 at 16:02
REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter 2022 after market close on Thursday, August 4, 2022. The company’s management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Seeking Alpha
Procept: Leveraging A Novel Water-Based System For Enlarged Prostate Treatment
Thursday May 26 2022 at 01:37
PROCEPT has developed a system to treat enlarged prostate disease, and is banking on competitive advantage over legacy treatment options. The common disease, more prevalent as populations grow older, provides the company with a large TAM to drive growth.
Seeking Alpha
PROCEPT BioRobotics Corporation (PRCT) CEO Reza Zadno on Q1 2022 Results – Earnings Call Transcript
Sunday May 08 2022 at 03:12
PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Matt Bacso – Investor Relations Reza Zadno – Chief Executive Officer Kevin Waters – Chief Financial Officer Conference Call Participants Josh Jennings – Cowen Craig Bijou – Bank of America Amit Hazan – Goldman Sachs Matt Bacso Thanks, operator. Good afternoon and thank you for participating in today’s call.
GlobeNewsWire
PROCEPT BioRobotics Corp. to Report First Quarter 2022 Financial Results on May 5, 2022 and attend the 2022 Bank of America Healthcare Conference on May 11, 2022
Tuesday Apr 12 2022 at 16:02
REDWOOD CITY, Calif., April 12, 2022 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter 2022 after market close on Thursday, May 5, 2022. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
GuruFocus
Andreas Halvorsen Powers Down Position in PROCEPT BioRobotics
Thursday Mar 24 2022 at 11:54
Viking Global leader Andreas Halvorsen (Trades, Portfolio) disclosed earlier this week he curbed his PROCEPT BioRobotics Corp. ( PRCT , Financial) stake by 25.45%.
Seeking Alpha
PROCEPT BioRobotics (PRCT) CEO Reza Zadno on Q4 2021 Results – Earnings Call Transcript
Tuesday Mar 08 2022 at 11:37
PROCEPT BioRobotics (PRCT) CEO Reza Zadno on Q4 2021 Results – Earnings Call Transcript
Benzinga
6 Underperforming IPO Stocks To Buy On The Dip
Friday Feb 04 2022 at 14:47
The U.S. IPO market was red-hot in 2021. The total number of traditional U.S. IPOs hit its highest level since the dot-com boom in the late 1990s, while total IPO deal value reached record levels last year.
Seeking Alpha
PROCEPT BioRobotics’ (PRCT) CEO Reza Zadno on Q3 2021 Results – Earnings Call Transcript
Sunday Nov 07 2021 at 08:05
PROCEPT BioRobotics’ (PRCT) CEO Reza Zadno on Q3 2021 Results – Earnings Call Transcript
PROCEPT BioRobotics Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
PROCEPT BioRobotics’s Altman Z-score is 5.82 which is in the safe zone. This indicates the company is financially stable and less likely to experience financial distress or bankruptcy.
Derived from SEC.GOV filing dataopen_in_new
PROCEPT BioRobotics Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has sold $316.13K of common stock in PROCEPT BioRobotics on the stock market with no insider buying.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
PROCEPT BioRobotics’s Income Quality of 0.91 is greater than its Industry Group of 0.68 (33.8% greater)
PROCEPT BioRobotics’s Income Quality of 0.91 is greater than its Major Industry Group of 0.71 (28.2% greater)
PROCEPT BioRobotics’s Income Quality of 0.91 is greater than its Sector of 0.75 (21.3% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
PROCEPT BioRobotics’s Current Ratio of 6.4 is greater than its Industry Group of 3.36 (90.5% greater)
PROCEPT BioRobotics’s Current Ratio of 6.4 is greater than its Major Industry Group of 3.13 (104.5% greater)
PROCEPT BioRobotics’s Current Ratio of 6.4 is greater than its Sector of 2.6 (146.2% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-14.25 & -1.02)
Cannot compare a negative PE Ratio (-14.25 & -0.58)
Cannot compare a negative PE Ratio (-14.25 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
PROCEPT BioRobotics’s PB Ratio of 9.82 is greater than its Industry Group of 1.9 (416.8% greater)
PROCEPT BioRobotics’s PB Ratio of 9.82 is greater than its Major Industry Group of 1.93 (408.8% greater)
PROCEPT BioRobotics’s PB Ratio of 9.82 is greater than its Sector of 1.62 (506.2% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
PROCEPT BioRobotics’s ROE of -0.69 is lower than its Industry Group of -0.26 (-165.4% lower)
PROCEPT BioRobotics’s ROE of -0.69 is lower than its Major Industry Group of -0.09 (-666.7% lower)
PROCEPT BioRobotics’s ROE of -0.69 is lower than its Sector of -0.03 (-2200.0% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
PROCEPT BioRobotics’s ROCE of -0.43 is lower than its Industry Group of -0.27 (-59.3% lower)
PROCEPT BioRobotics’s ROCE of -0.43 is lower than its Major Industry Group of -0.14 (-207.1% lower)
PROCEPT BioRobotics’s ROCE of -0.43 is lower than its Sector of -0.04 (-975.0% lower)
Derived from SEC.GOV filing dataopen_in_new